Key Insights

Highlights

Treatment Research

1 treatments under study, led by Efbemalenograstim Alfa

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07187908Phase 2Recruiting

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Showing all 1 trials

Research Network

Common Treatments

  • Efbemalenograstim Alfa1

Active Sponsors

  • West China Hospital1
  • Henan Cancer Hospital1

Related Conditions

  • High Risk For Febrile Neutropenia Of Chemotherapy Regimens1
  • Primarysecondary Prevention1

Activity Timeline